Avivia BV, a Dutch based pharmaceutical contract research organization company, is pleased to announce that Gert Jan Ettema will become the new Managing Director of
Meet Avivia at the 2022 CPhI Worldwide in Frankfurt. In early November we will be exhibiting at CPhI Worldwide 2022 in Frankfurt, Germany. The CPhI
Unrealized potential of drug repositioning in Europe during COVID-19 and beyond: a physician’s perspective
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs compared to de novo drug development. Clinical research groups recognizing efficacy of these “old” drugs for a new indications often face an uphill struggle due to a lack of funding and support because of poor structural and regulatory support for clinical drug development.
An international group of researchers, including Avivia CEO Hans Platteeuw, believe there is ample evidence that antimalarial drugs can be used to treat COVID-19 and that they should be assessed for their efficacy in clinical trials.
The research group, from institutions across Europe, Asia and Africa, point to a combination of the drugs artesunate and pyronaridine as the most promising.